Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
van der Werf I, Wojtuszkiewicz A, Yao H, Sciarrillo R, Meggendorfer M, Hutter S, Walter W, Janssen J, Kern W, Haferlach C, Haferlach T, Jansen G, Kaspers GJL, Groen R, Ossenkoppele G, Cloos J. van der Werf I, et al. Among authors: wojtuszkiewicz a. Leukemia. 2021 Sep;35(9):2735. doi: 10.1038/s41375-021-01340-z. Leukemia. 2021. PMID: 34272482 Free PMC article. No abstract available.
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
van der Werf I, Wojtuszkiewicz A, Yao H, Sciarrillo R, Meggendorfer M, Hutter S, Walter W, Janssen J, Kern W, Haferlach C, Haferlach T, Jansen G, Kaspers GJL, Groen R, Ossenkoppele G, Cloos J. van der Werf I, et al. Among authors: wojtuszkiewicz a. Leukemia. 2021 Sep;35(9):2698-2702. doi: 10.1038/s41375-021-01273-7. Epub 2021 May 17. Leukemia. 2021. PMID: 34002025 Free PMC article. No abstract available.
Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML.
Wojtuszkiewicz A, van der Werf I, Hutter S, Walter W, Baer C, Kern W, Janssen JJWM, Ossenkoppele GJ, Haferlach C, Cloos J, Haferlach T. Wojtuszkiewicz A, et al. Cancers (Basel). 2021 Aug 4;13(16):3929. doi: 10.3390/cancers13163929. Cancers (Basel). 2021. PMID: 34439083 Free PMC article.
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.
van der Werf I, Wojtuszkiewicz A, Meggendorfer M, Hutter S, Baer C, Heymans M, Valk PJM, Kern W, Haferlach C, Janssen JJWM, Ossenkoppele GJ, Cloos J, Haferlach T. van der Werf I, et al. Among authors: wojtuszkiewicz a. Blood Adv. 2021 Sep 14;5(17):3254-3265. doi: 10.1182/bloodadvances.2021004556. Blood Adv. 2021. PMID: 34448812 Free PMC article.
The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A, Assaraf YG, Hoekstra M, Sciarrillo R, Jansen G, Peters GJ, Pieters R, Sonneveld E, Escherich G, Kaspers GJ, Cloos J. Wojtuszkiewicz A, et al. Haematologica. 2016 Jul;101(7):e291-4. doi: 10.3324/haematol.2016.142794. Epub 2016 Apr 1. Haematologica. 2016. PMID: 27036162 Free PMC article. No abstract available.
The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R, Wojtuszkiewicz A, Assaraf YG, Jansen G, Kaspers GJL, Giovannetti E, Cloos J. Sciarrillo R, et al. Among authors: wojtuszkiewicz a. Drug Resist Updat. 2020 Dec;53:100728. doi: 10.1016/j.drup.2020.100728. Epub 2020 Sep 28. Drug Resist Updat. 2020. PMID: 33070093 Free article. Review.
17 results